Nykredit A S Purchases New Holdings in Abbott Laboratories $ABT

Key Points

• Nykredit A/S initiated a position in Abbott Laboratories, purchasing 548,577 shares valued at approximately $49.8 million. Institutional investors collectively own 75.18% of ABT’s outstanding stock.
• Analysts remain broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $119.50; several firms recently raised their targets or upgraded the stock.
• Abbott exceeded quarterly earnings and revenue estimates, reporting $1.31 in EPS and $12.59 billion in revenue, while revenue increased 13% year over year. The company also declared a quarterly dividend of $0.63 per share, representing a 2.5% yield.

Nykredit A S purchased a new position in Abbott Laboratories (NYSE:ABT - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 548,577 shares of the healthcare product maker's stock, valued at approximately $49,778,000.

Several other large investors also recently bought and sold shares of ABT. BlackRock Inc. boosted its stake in Abbott Laboratories by 4.6% in the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares during the period. State Street Corp raised its position in shares of Abbott Laboratories by 2.1% during the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker's stock valued at $10,004,880,000 after buying an additional 1,627,791 shares in the last quarter. Capital International Investors grew its position in Abbott Laboratories by 2.6% in the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker's stock worth $7,922,519,000 after acquiring an additional 1,614,706 shares in the last quarter. J. Stern & Co. LLP boosted its stake in Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock worth $4,926,279,000 after buying an additional 39,005,451 shares during the period. Finally, Capital Research Global Investors grew its stake in shares of Abbott Laboratories by 1.0% during the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker's stock valued at $4,907,523,000 after buying an additional 400,400 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on ABT shares. BTIG Research increased their target price on Abbott Laboratories from $131.00 to $134.00 and gave the stock a "buy" rating in a research note on Friday, July 17th. Piper Sandler restated an "overweight" rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Wolfe Research upgraded Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 target price for the company in a report on Thursday, August 13th. JPMorgan Chase & Co. upped their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an "overweight" rating in a research note on Friday, July 17th. Finally, Weiss Ratings raised shares of Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, August 6th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $119.50.

Abbott Laboratories Trading Up 0.1%

NYSE ABT opened at $102.35 on Friday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The company has a market capitalization of $177.11 billion, a PE ratio of 33.12, a P/E/G ratio of 1.89 and a beta of 0.59. The company has a fifty day moving average of $106.35 and a 200 day moving average of $99.40.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company's revenue was up 13.0% on a year-over-year basis. During the same quarter last year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories NYSE: ABT is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company's medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.